Zelgen(SH:688266) Xin Lang Cai Jing·2025-11-12 02:06Core Viewpoint - Zai Jian Pharmaceutical has shown a significant stock price increase of 59.32% year-to-date, despite recent fluctuations in trading performance [1][2] Company Overview - Zai Jian Pharmaceutical, established on March 18, 2009, and listed on January 23, 2020, is located in Kunshan, Jiangsu Province, and focuses on the research, production, and sales of chemical and biological new drugs [1][2] - The company's main revenue source is pharmaceuticals, accounting for 99.97% of total revenue, with minimal contributions from intermediates and asset leasing [1] Financial Performance - For the period from January to September 2025, Zai Jian Pharmaceutical reported a revenue of 593 million yuan, representing a year-on-year growth of 54.49% [2] - The company recorded a net profit attributable to shareholders of -93.42 million yuan, showing a year-on-year increase of 4.58% [2] Stock Market Activity - As of November 12, Zai Jian Pharmaceutical's stock price was 99.27 yuan per share, with a market capitalization of 26.278 billion yuan [1] - The stock has experienced a trading volume of 50.129 million yuan, with a turnover rate of 0.19% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of 187 million yuan on October 31 [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 8,809, with an average of 30,049 circulating shares per person [2] - Notable institutional shareholders include China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A, with varying changes in their holdings [2]